

Optum Coding for Coronavirus (COVID-19)

Below is an overview of and industry guidance for coding changes related to the 2019 novel coronavirus (COVID-19). Optum is committed to ensuring that you have the information you need to effectively and efficiently address COVID-19 from a medical coding, billing, and reimbursement perspective. We have compiled information from the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), American Medical Association (AMA), and the Centers for Medicare and Medicaid Services (CMS), so you can easily access the most up-to-date medical code detail and effective dates in one convenient place. Use the following to link to the sections within this document:

[CPT Codes](#) | [HCPCS Codes](#) | [Vaccine Table](#) | [Monoclonal Antibodies](#) | [ICD-10-CM/ICD-10-PCS](#) | [Vaccines - Dental](#)

CPT Codes

| The American Medical Association (AMA) has issued the following codes to the CPT Procedure Coding System. Additional information can be found at https://www.ama-assn.org/practice-management/cpt . | | | | |
|--|---|----------------|----------|---|
| Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Related CPT Codes | | | | |
| Code | Descriptor | Effective Date | End Date | Location in Optum coding product, <i>Current Procedural Coding Expert</i> |
| 86318 | Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single-step method (eg, reagent strip); | 04/10/2020 | N/A | N/A |
| 86769 | Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 04/10/2020 | N/A | N/A |
| 87426 | Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) | 01/01/2022 | N/A | N/A |
| 87428 | Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B | 11/10/2020 | N/A | N/A |
| 87635 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 03/13/2020 | N/A | N/A |
| 87636 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique | 10/06/2020 | N/A | N/A |
| 87637 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique | 10/06/2020 | N/A | N/A |
| #86328 | Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 04/10/2020 | N/A | Resequenced code. See code following 86318. |
| #86408 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); screen | 08/10/2020 | N/A | Resequenced code. See code following 86382. |
| #86409 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); titer | 08/10/2020 | N/A | Resequenced code. See code following 86382. |
| #86413 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) antibody, quantitative | 09/08/2020 | N/A | Resequenced code. See code following resequenced code 86409. |
| #87811 | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 10/06/2020 | N/A | Resequenced code. See code following 87807. |
| #87913 | Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s) | 02/21/2022 | N/A | Resequenced code. See code following 87902. |
| #91300 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use | 12/11/2020 | N/A | Resequenced code. See code before 90476. |

| | | | | |
|--------|---|------------|-----|--|
| #91301 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use | 12/18/2020 | N/A | Resequenced code. See code before 90476. |
| #91302 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use | 12/17/2020 | N/A | Resequenced code. See code before 90476. |
| #91303 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use | 02/27/2021 | N/A | Resequenced code. See code before 90476. |
| #91304 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use | 05/04/2021 | N/A | Resequenced code. See code before 90476. |
| #91305 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 10/29/2021 | N/A | Resequenced code. See code before 90476. |
| #91306 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use | 10/20/2021 | N/A | Resequenced code. See code before 90476. |
| #91307 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | 10/29/2021 | N/A | Resequenced code. See code before 90476. |
| #91308 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | 6/17/2022 | N/A | Resequenced code. See code before 90476. |
| #91309 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use | 3/7/2022 | N/A | Resequenced code. See code before 90476. |
| #91310 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use | 4/26/2022 | N/A | Resequenced code. See code before 90476. |
| #91311 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | 06/17/2022 | N/A | Resequenced code. See code before 90476. |
| #91312 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 08/31/2022 | N/A | Resequenced code. See code before 90476. |
| #91313 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use | 08/31/2022 | N/A | Resequenced code. See code before 90476. |
| #91314 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | 08/31/2022 | N/A | Resequenced code. See code before 90476. |
| #91315 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | 08/31/2022 | N/A | Resequenced code. See code before 90476. |
| 99072 | Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other nonfacility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease | | N/A | N/A |
| 0001A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose | 12/11/2020 | N/A | N/A |

| | | | | |
|--------|---|------------|-----|--|
| 0002A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose | 12/11/2020 | N/A | N/A |
| 0003A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose | 08/12/2021 | N/A | N/A |
| 0004A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose | 09/22/2021 | N/A | N/A |
| 0011A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose | 12/18/2020 | N/A | N/A |
| 0012A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose | 12/18/2020 | N/A | N/A |
| 0013A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose | 08/12/2021 | N/A | N/A |
| #0021A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; first dose | 12/17/2020 | N/A | Resequenced code. See code following 90474. |
| #0022A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; second dose | 12/17/2020 | N/A | Resequenced code. See code following 90474. |
| 0031A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; single dose | 10/20/2021 | N/A | Resequenced code. See code following 90474. |
| 0034A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; booster dose | 10/20/2021 | N/A | N/A |
| 0041A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose | 07/13/2021 | N/A | N/A |
| 0042A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose | 07/13/2021 | N/A | N/A |
| #0051A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose | 10/29/2021 | N/A | Resequenced code. See code following resequenced code 0004A. |
| #0052A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose | 10/29/2021 | N/A | Resequenced code. See code following resequenced code 0004A. |
| #0053A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose | 10/29/2021 | N/A | Resequenced code. See code following resequenced code 0004A. |
| #0054A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose | 10/29/2021 | N/A | Resequenced code. See code following resequenced code 0004A. |

| | | | | |
|--------|---|------------|-----|--|
| #0064A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose | 10/20/2021 | N/A | Resequenced code. See code following resequenced code 0013A. |
| #0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 10/29/2021 | N/A | Resequenced code. See code following resequenced code 0054A. |
| #0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 10/29/2021 | N/A | Resequenced code. See code following resequenced code 0054A. |
| #0073A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose | 01/03/2022 | N/A | Resequenced code. See code following resequenced code 0054A. |
| #0074A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose | 05/17/2022 | N/A | Resequenced code. See code following resequenced code 0054A. |
| #0081A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 06/17/2022 | N/A | Resequenced code. See code 90474. |
| #0082A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 06/17/2022 | N/A | Resequenced code. See code following 90474. |
| #0083A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose | 06/17/2022 | N/A | Resequenced code. See code following 90474. |
| #0091A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years | 06/17/2022 | N/A | Resequenced code. See code following 90474. |
| #0092A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years | 06/17/2022 | N/A | Resequenced code. See code following 90474. |
| #0093A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years | 06/17/2022 | N/A | Resequenced code. See code following 90474. |
| #0094A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; booster dose, when administered to individuals 18 years and over | 03/29/2022 | N/A | Resequenced code. See code following 90474. |
| 0104A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose | 04/26/2022 | N/A | N/A |
| 0111A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose | 06/17/2022 | N/A | N/A |
| 0112A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose | 06/17/2022 | N/A | N/A |

| | | | | |
|---|--|------------|-----|--|
| 0113A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose | 06/17/2022 | N/A | N/A |
| #0124A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose | 08/31/2022 | N/A | Resequenced code. See code following resequenced code 0054A. |
| #0134A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose | 08/31/2022 | N/A | Resequenced code. See code following resequenced code 0064A. |
| #0144A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose | 08/31/2022 | N/A | Resequenced code. See code following resequenced code 0064A. |
| #0154A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose | 08/31/2022 | N/A | Resequenced code. See code following resequenced code 0074A. |
| 0202U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected | 05/20/2020 | N/A | N/A |
| 0223U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected | 06/25/2020 | N/A | N/A |
| 0224U | Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), includes titer(s), when performed | 06/25/2020 | N/A | N/A |
| 0225U | Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected | 08/10/2020 | N/A | N/A |
| 0226U | Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), ELISA, plasma, serum | 08/10/2020 | N/A | N/A |
| 0240U | Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected | 10/06/2020 | N/A | N/A |
| 0241U | Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected | 10/06/2020 | N/A | N/A |
| Notes: | | | | |
| # Resequenced Code ↗ Non-FDA Drug | | | | |
| A CPT code and HCPCS code should not be reported together for COVID-19 testing, vaccines, or monoclonal antibody therapy. Providers should contact third-party payer(s) for their guidance on whether to report a CPT or a HCPCS code, as well as for retroactive billing and reimbursement guidelines. | | | | |
| CPT © 2022 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. | | | | |

HCPCS Codes

The Centers for Medicare and Medicaid Services (CMS) has issued the following codes to the HCPCS Procedure Coding System. Additional information can be found at <https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/HCPCS-Quarterly-Update>.

| Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Related HCPCS Codes | | | |
|--|--|-----------------------|-----------------|
| Code | Descriptor | Effective Date | End Date |
| G0314 | Immunization counseling by a physician or other qualified health care professional for COVID-19, ages under 21, 16-30 minutes time (This code is used for the Medicaid Early and Periodic Screening, Diagnostic, and Treatment Benefit [EPSDT]) | 4/1/2021 | N/A |
| G0315 | Immunization counseling by a physician or other qualified health care professional for COVID-19, ages under 21, 5-15 minutes time (This code is used for the Medicaid Early and Periodic Screening, Diagnostic, and Treatment Benefit [EPSDT]) | 4/1/2021 | N/A |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), any specimen source | 03/01/2020 | N/A |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), any specimen source | 03/01/2020 | N/A |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) from an individual in a SNF or by a laboratory on behalf of a HHA, any specimen source | 03/01/2020 | N/A |
| J0248 | Injection, remdesivir, 1 mg | 12/23/2021 | N/A |
| M0201 | COVID-19 vaccine administration inside a patient's home; reported only once per individual home, per date of service, when only COVID-19 vaccine administration is performed at the patient's home | 05/26/2021 | N/A |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring | 12/08/2021 | N/A |
| M0221 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID -19 vaccine(s) and/or COVID -19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID -19 public health emergency | 12/08/2021 | N/A |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | 02/11/2022 | N/A |
| M0223 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency | 02/11/2022 | N/A |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 11/10/2020 | 4/17/2021 |
| M0240 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring, subsequent repeat doses | 07/30/2021 | N/A |
| M0241 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection, and post administration monitoring in the home or residence. This includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses | 07/30/2021 | N/A |
| M0243 | Intravenous infusion, casirivimab and imdevimab, includes infusion and post administration monitoring | 11/21/2020 | N/A |
| M0244 | Intravenous infusion, casirivimab and imdevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency | 05/6/2021 | N/A |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 02/09/2021 | N/A |
| M0246 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency | 05/06/2021 | N/A |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | 05/26/2021 | N/A |
| M0248 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency | 05/26/2021 | N/A |
| M0249 | Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose | 06/24/2021 | N/A |

| | | | |
|---|---|------------|-----------|
| M0250 | Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose | 06/24/2021 | N/A |
| Q0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 300 mg | 12/08/2021 | N/A |
| Q0222 | Injection, bebtelovimab, 175 mg | 02/11/2022 | N/A |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 11/10/2020 | 4/17/2021 |
| Q0240 | Injection, casirivimab and imdevimab, 600 mg | 07/30/2021 | N/A |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 11/21/2020 | N/A |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 02/09/2021 | N/A |
| Q0247 | Injection, sotrovimab, 500 mg | 05/26/2021 | N/A |
| Q0249 | Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg | 06/24/2021 | N/A |
| U0001 | CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel | 02/04/2020 | N/A |
| U0002 | 2019-nCoV coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC | 02/04/2020 | N/A |
| U0003 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R | 04/14/2020 | N/A |
| U0004 | 2019-nCoV coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R | 04/14/2020 | N/A |
| U0005 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) as described by CMS-2020-01-R2 | 01/01/2021 | N/A |
| <p><i>A CPT code and HCPCS code should not be reported together for COVID-19 testing, vaccines, or monoclonal antibody therapy. Providers should contact third-party payer(s) for their guidance on whether to report a CPT or a HCPCS code, as well as for retroactive billing and reimbursement guidelines.</i></p> | | | |

Vaccine Table

| Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccine and Administration Codes | | | | | | | | |
|---|---|---|--------------|---|--|---|--------------------|----------------|
| The following table provides a link between each individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine code and its corresponding vaccine administration code, along with the vaccine manufacturer name, vaccine name, National Drug Code (NDC) Labeler Product ID number(s), the recommended interval between vaccine doses, and the effective date. These resequenced codes are located in the Medicine section. Additional instructional notes can be found with the codes in the appropriate code ranges or at https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes . Information regarding FDA EUA processes and dates can be found at https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#vaccines . | | | | | | | | |
| Vaccine Code | Long Descriptor | Administration Code(s) | Manufacturer | Vaccine Name(s) | NDC 10/ NDC 11 Labeler Product ID (vial) | Dosing Interval | Patient Age | Effective Date |
| #91300 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use | 0001A (1st dose) 0002A (2nd dose) 0003A (3rd dose) 0004A (booster dose) | Pfizer, Inc | Pfizer-BioNTech COVID-19 Vaccine; Comirnaty | 59267-1000-1 59267-1000-01 | 1st to 2nd dose: 21 days 2nd to 3rd dose: 28 or more days Booster: See FDA/CDC Guidance | 12 years and older | 12/11/2020 |
| #91305 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | #0051A (1st dose) #0052A (2nd dose) #0053A (3rd dose) #0054A (booster dose) | Pfizer, Inc | Pfizer-BioNTech COVID-19 Vaccine/ Comirnaty | 59267-1025-1 59267-1025-01 00069-2025-1 00069-2025-01 | 1st to 2nd dose: 21 days 2nd to 3rd dose: 28 or more days Booster: See FDA/CDC Guidance | 12 years and older | 10/29/2021 |
| #91312 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | #0124A (booster dose) | Pfizer, Inc | Pfizer-BioNTech COVID-19 Bivalent | 59267-0304-1 59267-0304-01 59267-1404-1 59267-1404-01 | See FDA/CDC Guidance | 12 years and older | 08/31/2022 |
| #91307 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | #0071A (1st dose) #0072A (2nd dose) #0073A (3rd dose) # 0074A (booster dose) | Pfizer, Inc | Pfizer-BioNTech COVID-19 Vaccine | 59267-1055-1 59267-1055-01 | 1st to 2nd dose: 21 days 2nd to 3rd dose: 28 or more days Booster: See FDA/CDC Guidance | 5-11 years | 10/29/2021 |
| #91315 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | #0154A (booster dose) | Pfizer, Inc | Pfizer-BioNTech COVID-19 Bivalent | 59267-0565-1 59267-0565-01 | See FDA/CDC Guidance | 5-11 years | 08/31/2022 |

| | | | | | | | | |
|--------|---|--|------------------|------------------------------------|--|---|--|------------|
| #91308 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | # 0081A (1st dose) # 0082A (2nd dose) # 0083A (3rd dose) | Pfizer, Inc | Pfizer-BioNTech COVID-19 Vaccine | 59267-0078-1 59267-0078-01 59267-0078-4 59267-0078-04 | 1st to 2nd dose: 21 days 2nd to 3rd dose: See FDA/CDC Guidance | 6 months - 4 years | 06/17/2022 |
| #91301 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use | 0011A (1st dose) 0012A (2nd dose) 0013A (3rd dose) | Moderna, Inc | Moderna COVID-19 Vaccine/spikevax | 80777-273-10 80777-0273-10 80777-100-11 80777-0100-11 | 1st to 2nd dose: 28 days 2nd to 3rd dose: 28 or more days See FDA/CDC Guidance | 12 years and older | 12/18/2020 |
| #91306 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use | #0064A (booster dose) | Moderna, Inc | Moderna COVID-19 Vaccine | 80777-273-10 80777-0273-10 | See FDA/CDC Guidance | 18 years and older | 10/20/2021 |
| #91313 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use | #0134A (booster dose) | Moderna, Inc | Moderna COVID-19 Vaccine, Bivalent | 80777-282-05 80777-0282-05 | See FDA/CDC Guidance | 18 years and older | 08/31/2022 |
| #91314 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | #0144A (booster dose) | Moderna, Inc | Moderna COVID-19 Vaccine, Bivalent | 80777-282-05 80777-0282-05 | See FDA/CDC Guidance | 6-11 years | 08/31/2022 |
| #91311 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | 0111A (1st dose) 0112A (2nd dose) 0113A (3rd dose) | Moderna, Inc | Moderna COVID-19 Vaccine | 80777-279-05 80777-0279-05 | 1st to 2nd dose: 1 month 2nd to 3rd dose: 1 month | 6 months - 5 years | 06/17/2022 |
| #91309 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use | # 0091A (1st dose) # 0092A (2nd dose) # 0093A (3rd dose) # 0094A (booster dose) | Moderna, Inc | Moderna COVID-19 Vaccine | 80777-275-05 80777-0275-05 | 1st to 2nd dose: 1 month 2nd to 3rd dose: 1 month Booster: See FDA/CDC Guidance | 6-11 years (0091A-0093A) 18 years and older (0094A) | 03/29/2022 |
| #91302 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use | 0021A (1st dose) 0022A (2nd dose) | AstraZeneca, Plc | AstraZeneca COVID-19 Vaccine | 0310-1222-10 00310-1222-10 | 28 days | 18 years and older | 12/17/2020 |

| | | | | | | | | |
|---|--|---|----------------|---------------------------------|-------------------------------|-------------------------------|--------------------|------------|
| #91303 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ^{>10</sup> viral particles/0.5mL dosage, for intramuscular use} | 0031A (single dose) 0034A (booster dose) | Janssen | Janssen COVID-19 Vaccine | 59676-580-05 59676-0580-05 | Booster: See FDA/CDC Guidance | 18 years and older | 02/27/2021 |
| # 91304 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use | 0041A (1st dose) 0042A (2nd dose) | Novavax, Inc | Novavax COVID-19 Vaccine | 80631-100-01 80631-1000-01 | 21 days | 18 years and older | 07/13/2022 |
| # 91310 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use | 0104A (booster dose) | Sanofi Pasteur | Sanofi Pasteur COVID-19 Vaccine | 49281-618-20 49281-0618-20 | See FDA/CDC Guidance | 18 years and older | 04/26/2022 |
| Notes: # Resequenced Code Non-FDA Drug | | | | | | | | |
| COVID-19 vaccine drug codes [91300, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309, 91310, 91311, 91312, 91313, 91314, 91315] are exempt from reporting with modifier 51. | | | | | | | | |
| COVID-19 vaccine administration codes 0001A-0004A, 0011A-0013A, 0021A-0022A, 0031A, 0034A, 0041A-0042A, [0051A-0054A], [0124A], [0064A], [0134A], [0144A], [0071A-0074A], [0154A], [0081A-0083A], [00091-0094A], 0104A and 0111A-0113A should be reported with vaccine codes [91300, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309, 91310, 91311, 91312, 91313, 91314, 91315] <i>only</i> . All other vaccines should be reported with [90460-90461], 90471-90472, 90474, 90476-90759. COVID-19 vaccine administration codes should not be reported with other immunization administration codes unless an additional vaccine/toxoid is administered during the same visit. | | | | | | | | |
| CPT © 2022 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. | | | | | | | | |

Monoclonal Antibodies

| Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Monoclonal Antibody and Administration Codes | | | | | | |
|--|---|------------------------|-----------------|-----------------------------|---|--|
| The following table provides a link between each individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) monoclonal antibody code and its corresponding administration code(s), along with the manufacturer name, brand name (when available), National Drug Code (NDC) Labeler Product ID number(s), and the effective date. Additional instructional notes can be found with the codes in the appropriate code ranges or at https://www.cms.gov/medicare/covid-19/monoclonal-antibody-covid-19-infusion . Information regarding FDA EUA processes and dates can be found at https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs . | | | | | | |
| Code | Long Descriptor | Administration Code(s) | Manufacturer | Brand Name (When Available) | NDC 10/NDC 11 Labeler Product ID (vial) | Effective Date |
| J0248 | Injection, remdesivir, 1 mg | 96365 96366 | Gilead | Veklury | 61958-2901-1 61958-2901-2 61958-2902-2 | 12/23/2021 |
| Q0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 300 mg | M0220 M0221 | AstraZeneca | Evusheld | 0310-7442-02 | 12/08/2021 |
| Q0222 | Injection, bebtelovimab, 175 mg | M0222 M0223 | Eli Lilly | N/A | Not Available | 02/11/2022 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | M0239 | Eli Lilly | N/A | 00002-7910-01 | EUA revoked 04/15/2021 when administered alone |
| Q0240 | Injection, casirivimab and imdevimab, 600 mg | M0240 M0241 | Regeneron | REGEN-COV | 61755-0026-01 61755-0024-01 61755-0025-01 61755-0027-01 61755-0039-01 61755-0035-02 61755-0036-08 | 07/30/2021 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | M0243 M0244 | Regeneron | REGEN-COV | 61755-0024-01 61755-0026-01 61755-0025-01 61755-0027-01 61755-0039-01 61755-0035-02 61755-0036-08 | 05/06/2021 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | M0243 M0244 | Regeneron | REGEN-COV | 61755-0039-01 61755-0039-01 61755-0035-02 61755-0036-08 | 06/03/2021 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | M0245 M0246 | Eli Lilly | N/A | 00002-7910-01 00002-7950-01 | 05/06/2021 |
| Q0247 | Injection, sotrovimab, 500 mg | M0247 M0248 | GlaxoSmithKline | N/A | 00173-0901-86 | 05/26/2021 |
| Q0249 | Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg | M0249 M0250 | Genentech | Actemra | 50242-0135-01 50242-0136-01 50242-0137-01 | 06/24/2021 |

ICD-10-CM and ICD-10-PCS Codes

The Centers for Disease Control and Prevention's (CDC) National Center for Health Statistics (NCHS), the federal agency responsible for maintaining the International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Clinical Modification (ICD-10-CM) in the United States, implemented the following ICD-10-CM codes:

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Related ICD-10-CM Codes

| Code | Description | Effective Date |
|---------|---|----------------|
| J12.82 | Pneumonia due to coronavirus disease 2019 | 01/01/2021 |
| M35.81 | Multisystem inflammatory syndrome | 01/01/2021 |
| U07.1 | COVID-19 | 04/01/2020 |
| U09.9 | Post COVID-19 condition, unspecified | 10/01/2021 |
| Z11.52 | Encounter for screening for COVID-19 | 01/01/2021 |
| Z20.822 | Contact with and (suspected) exposure to COVID-19 | 01/01/2021 |
| Z28.310 | Unvaccinated for COVID-19 | 04/01/2022 |
| Z28.311 | Partially vaccinated for COVID-19 | 04/01/2022 |
| Z86.16 | Personal history of COVID-19 | 01/01/2021 |

The Centers for Medicare and Medicaid Services (CMS) has issued the following procedure codes to the International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS). These codes describe the introduction or infusion of therapeutics or current treatments used to manage COVID-19 patients. These codes do not affect MS-DRG assignment.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Related ICD-10-PCS Codes

| Code | Description | Effective Date |
|---------|--|----------------|
| XW013F5 | Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 | 08/01/2020 |
| XW013H6 | Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW013K6 | Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW013S6 | Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW013T6 | Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW013U6 | Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW013V7 | Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 | 04/01/2022 |
| XW013W7 | Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 | 04/01/2022 |
| XW023X7 | Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 | 04/01/2022 |
| XW023Y7 | Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 | 04/01/2022 |
| XW023S6 | Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW023T6 | Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW023U6 | Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW023V7 | Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7 | 04/01/2022 |
| XW023W7 | Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7 | 04/01/2022 |
| XW033E5 | Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | 08/01/2020 |
| XW033E6 | Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW033F5 | Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | 08/01/2020 |
| XW033F6 | Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW033G5 | Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | 08/01/2020 |
| XW033G6 | Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW033H5 | Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | 08/01/2020 |

| | | |
|---------|--|------------|
| XW033H6 | Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW033L6 | Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW043E5 | Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5 | 08/01/2020 |
| XW043E6 | Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW043F5 | Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5 | 08/01/2020 |
| XW043F6 | Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW043G5 | Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5 | 08/01/2020 |
| XW043G6 | Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW043H5 | Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5 | 08/01/2020 |
| XW043H6 | Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW043L6 | Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6 | 01/01/2021 |
| XW0DXF5 | Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5 | 08/01/2020 |
| XW0DXM6 | Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6 | 01/01/2021 |
| XW0DXR7 | Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7 | 04/01/2022 |
| XW0G7M6 | Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6 | 01/01/2021 |
| XW0G7R7 | Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7 | 04/01/2022 |
| XW0H7M6 | Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6 | 01/01/2021 |
| XW0H7R7 | Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7 | 04/01/2022 |
| XW13325 | Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | 08/01/2020 |
| XW14325 | Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5 | 08/01/2020 |

Vaccines - Dental

| Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccine and Administration Codes, Dental Providers | | | | | | | |
|--|--|---|-------------------------|---|--|--|-----------------------|
| <p>The following table provides a link between each individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine code to the vaccine manufacturer name, vaccine name, National Drug Code (NDC) Labeler Product ID number(s), the recommended interval between vaccine doses, and the effective date. These codes are only for use within a dental practice. Additional information about these codes can be found at https://www.ada.org/publications/cdt. Information regarding FDA EUA processes and dates can be found at https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#vaccines.</p> | | | | | | | |
| Vaccine Code | Long Descriptor | Usage Description | Manufacturer | Vaccine Name(s) | NDC 10/NDC 11 Labeler Product ID (vial) | Dosing Interval | Effective Date |
| D1701 | Pfizer-BioNTech Covid-19 vaccine administration-first dose | SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE 1 | Pfizer, Inc | Pfizer-BioNTech COVID-19 Vaccine; Comirnaty | 59267-1000-1 59267-1000-01 | 1st to 2nd dose: 21 days | 1/1/2021 |
| D1702 | Pfizer-BioNTech Covid-19 vaccine administration-second dose | SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE 2 | Pfizer, Inc | Pfizer-BioNTech COVID-19 Vaccine; Comirnaty | 59267-1000-1 59267-1000-01 | 1st to 2nd dose: 21 days 2nd to 3rd dose: 28 or more days | 1/1/2021 |
| D1703 | Moderna Covid-19 vaccine administration-first dose | SARSCOV2 COVID-19 VAC mRNA 100mcg/0.5mL IM DOSE 1 | Moderna, Inc | Moderna COVID-19 Vaccine | 80777-273-10 80777-0273-10 | 1st to 2nd dose: 28 days | 1/1/2021 |
| D1704 | Moderna Covid-19 vaccine administration-second dose | SARSCOV2 COVID-19 VAC mRNA 100mcg/0.5mL IM DOSE 2 | Moderna, Inc | Moderna COVID-19 Vaccine | 80777-273-10 80777-0273-10 | 1st to 2nd dose: 28 days 2nd to 3rd dose: 28 or more days | 1/1/2021 |
| D1705 | AstraZeneca Covid-19 vaccine administration-first dose | SARSCOV2 COVID-19 VAC rS-ChAdOx1 5x1010 VP/.5mL IM DOSE 1 | AstraZeneca, Plc | AstraZeneca COVID-19 Vaccine | 0310-1222-10 00310-1222-10 | 28 days | 1/1/2021 |
| D1706 | AstraZeneca Covid-19 vaccine administration-second dose | SARSCOV2 COVID-19 VAC rS-ChAdOx1 5x1010 VP/.5mL IM DOSE 2 | AstraZeneca, Plc | AstraZeneca COVID-19 Vaccine | 0310-1222-10 00310-1222-10 | 28 days | 1/1/2021 |
| D1707 | Janssen Covid-19 vaccine administration | SARSCOV2 COVID-19 VAC Ad26 5x1010 VP/.5mL IM SINGLE DOSE | Janssen | Janssen COVID-19 Vaccine | 59676-580-05 59676-0580-05 | N/A | 1/1/2021 |
| D1708 | Pfizer-BioNTech Covid-19 vaccine administration-third dose | SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE 3 | Pfizer, Inc | Pfizer-BioNTech COVID-19 Vaccine; Comirnaty | 59267-1000-1 59267-1000-01 | 2nd to 3rd dose: 28 or more days | 1/1/2022 |
| D1709 | Pfizer-BioNTech Covid-19 vaccine administration-booster dose | SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE BOOSTER | Pfizer, Inc | Pfizer-BioNTech COVID-19 Vaccine; Comirnaty | 59267-1000-1 59267-1000-01 | Booster: See FDA/CDC Guidance | 1/1/2022 |
| D1710 | Moderna Covid-19 vaccine administration-third dose | SARSCOV2 COVID-19 VAC mRNA 100mcg/0.5mL IM DOSE 3 | Moderna, Inc | Moderna COVID-19 Vaccine | 80777-273-10 80777-0273-10 | See FDA/CDC Guidance | 1/1/2022 |
| D1711 | Moderna Covid-19 vaccine administration-booster dose | SARSCOV2 COVID-19 VAC mRNA 50mcg/0.25mL IM DOSE BOOSTER | Moderna, Inc | Moderna COVID-19 Vaccine | 80777-273-10 80777-0273-10 | See FDA/CDC Guidance | 1/1/2022 |
| D1712 | Janssen Covid-19 vaccine administration-booster dose | SARSCOV2 COVID-19 VAC Ad26 5x1010 VP/0.5mL IM DOSE BOOSTER | Janssen | Janssen COVID-19 Vaccine | 59676-580-05 59676-0580-05 | See FDA/CDC Guidance | 1/1/2022 |
| D1713 | Pfizer-BioNTech Covid-19 vaccine administration tris-sucrose pediatric-first dose | SARSCOV2 COVID-19 VAC mRNA 10mcg/0.2mL tris-sucrose IM DOSE 1 | Pfizer, Inc | Pfizer-BioNTech COVID-19 Vaccine | 59267-1055-1 59267-1055-01 | 1st to 2nd dose: 21 days | 1/1/2022 |
| D1714 | Pfizer-BioNTech Covid-19 vaccine administration tris-sucrose pediatric-second dose | SARSCOV2 COVID-19 VAC mRNA 10mcg/0.2mL tris-sucrose IM DOSE 2 | Pfizer, Inc | Pfizer-BioNTech COVID-19 Vaccine | 59267-1055-1 59267-1055-01 | 1st to 2nd dose: 21 days | 1/1/2022 |